Telix Pharmaceuticals Limited (ASX:TLX)
16.19
+1.15 (7.65%)
Aug 7, 2026, 4:10 PM AEST
Telix Pharmaceuticals Revenue
In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M USD with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 122.47% growth.
Revenue
$803.79M
Revenue Growth
+55.61%
P/S Ratio
4.24
Revenue / Employee
$678.88K
Employees
1,184
Market Cap
5.11B AUD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.24% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.88% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.10B |
| Mesoblast | 98.02M |
| Clinuvel Pharmaceuticals | 96.30M |
| Neuren Pharmaceuticals | 64.65M |
| BLS Pharmaceuticals | 47.95M |
| PYC Therapeutics | 20.56M |
| Starpharma Holdings | 14.58M |
| Clarity Pharmaceuticals | 10.58M |
Telix Pharmaceuticals News
- 1 day ago - Telix to Host R&D Day in New York City on September 22, 2026 - GlobeNewsWire
- 16 days ago - TLX591-Tx ProstACT SELECT Study Published in Cancers Journal - GlobeNewsWire
- 17 days ago - Telix Pharma Q2 Revenue Rises 21%; Doses First Patient In Phase 3 LUTEON Trial; Shares Jump - Nasdaq
- 17 days ago - Telix Pharmaceuticals (TLX) Reports Strong Q2 Revenue Growth and Upbeat FY 2026 Outlook - GuruFocus
- 17 days ago - Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business - Nasdaq
- 17 days ago - Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewsWire
- 17 days ago - Telix Pharmaceuticals Earnings release: Q2 2026 - Filings
- 17 days ago - Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer - GlobeNewsWire